Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals

International Journal of Pharmaceutics

Volumn 433, Issue 1-2, 2012, Pages 157-164

  Hao, Leilei ^a   Wang, Xiaoyong ^b   Zhang, Dianrui ^a   Xu, Qingyan ^b   Song, Siyang ^b   Wang, Feihu ^a   Li, Caiyun ^a   Guo, Hejian ^a   Liu, Yue ^a   Zheng, Dandan ^a   Zhang, Qiang ^c  

^a SHANDONG UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Amoitone B; In vitro dissolution; Microfluidization method; Nanocrystals; Pharmacokinetics

Indexed keywords

AMOITONE B; ANTINEOPLASTIC AGENT; CRYSTALLIN; NANOCRYSTAL; NUCLEAR RECEPTOR NUR77; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MICROFLUIDIC ANALYSIS; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG COMPOUNDING; MICROFLUIDICS; NANOPARTICLES; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PARTICLE SIZE; PHENYLACETATES; RABBITS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; X-RAY DIFFRACTION;

EID: 84862842183     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.05.002     Document Type: Article

References (43)

1. Böhm, B.H., Müller, R.H., 1999. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm. Sci. Technol. Today 2, 336-339. (Pubitemid 29378538)
2. Bonta, P.I., Pols, T.W., de Vries, C.J., 2007. NR4A nuclear receptors in atherosclerosis and vein-graft disease. Trends Cardiovasc. Med. 17, 105-111. (Pubitemid 46518167)
3. Brady, S.F., Wagenaar, M.M., Singh, M.P., Janso, J.E., Clardy, J., 2000. The cytosporones, new octaketide antibiotics isolated from an endophytic fungus. Org. Lett. 2, 4043-4046.
4. Cerdeira, A.M., Mazzotti, M., Gander, B., 2010. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int. J. Pharm. 396, 210-218.
5. Chan, B.C., Ching, A.K., To, K.F., Leung, J.C., Chen, S., Li, Q., Lai, P.B., Tang, N.L., Shaw, P.C., Chan, J.Y., James, A.E., Lai, K.N., Lim, P.L., Lee, K.K., Chui, Y.L., 2008. BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma. Oncogene 27, 1208-1217. (Pubitemid 351294683)
6. Chen, H.B., Wan, J.L., Wang, Y.R., Mou, D.S., Liu, H.B., Xu, H.B., Yang, X.L., 2008. A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactions. Nanotechnology 19, 375104.
7. Chen, H.B., Khemtong, C., Yang, X.L., Chang, X.L., Gao, J.M., 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 16, 354-360.
8. Chen, J.F., Zhou, M.Y., Shao, L., Wang, Y.Y., Yun, J., Chew, N.Y., Chan, H.K., 2004. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int. J. Pharm. 269, 267-274. (Pubitemid 38032839)
9. Cho, S.D., Yoon, K., Chintharlapalli, S., Abdelrahim, M., Lei, P., Hamilton, S., Khan, S., Ramaiah, S.K., Safe, S., 2007. Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. Cancer Res. 67, 674-683. (Pubitemid 46192207)
10. Dolenc, A., Kristl, J., Baumgartner, S., Planinsek, O., 2009. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 376, 204-212.
11. Dressman, J.B., Amidon, G.L., Shah, V.P., Reppas, C., 1998. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15, 11-22. (Pubitemid 28080861)
12. Fakes, M.G., Vakkalagadda, B.J., Qian, F., Desikan, S., Gandhi, R.B., Lai, C., Hsieh, A., Franchini, M.K., Toale, H., Brown, J., 2009. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int. J. Pharm. 370, 167-174.
13. Gao, L., Zhang, D.R., Chen, M.H., 2008a. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 10, 845-862.
14. Gao, L., Zhang, D.R., Chen, M.H., Duan, C.X., Dai, W.T., Jia, L.J., Zhao, W.F., 2008b. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355, 321-327.
15. Gao, Y., Li, Z.G., Sun, M., Li, H.L., Guo, C.Y., Cui, J., Li, A.G., Cao, F.L., Xi, Y.W., Lou, H.X., Zhai, G.X., 2010. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev. Ind. Pharm. 36, 1225-1234.
16. Kayser, O., 2001. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int. J. Pharm. 214, 83-85. (Pubitemid 32244083)
17. Keck, C.M., Muller, R.H., 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62, 3-16. (Pubitemid 41736019)
18. Kolluri, S.K., Bruey-Sedano, N., Cao, X., Lin, B., Lin, F., Han, Y.-H., Dawson, M.I., Zhang, X.K., 2003. Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol. Cell. Biol. 23, 8651-8667. (Pubitemid 37433369)
19. Latha, S., Selvamani, P., Kumar, C.S., Sharavanan, P., Suganya, G., Beniwal, V.S., Rao, P.R., 2009. Formulation development and evaluation of metronidazole magnetic nanosuspension as a magnetic-targeted and polymeric-controlled drug delivery system. J. Magn. Magn. Mater. 321, 1580-1585.
20. Li, Q., Ching, A.K., Chan, B.C., Chow, S.K., Lim, P.L., Ho, T.C., Ip, W.K., Wong, C.K., Lam, C.W., Lee, K.K., Chan, J.Y., Chui, Y.L., 2004. A death receptor-associated antiapoptotic protein, BRE, inhibits mitochondrial apoptotic pathway. J. Biol. Chem. 279, 52106-52116. (Pubitemid 39656583)
21. Li, Q.-X., Ke, N., Sundaram, R., Wong-Staal, F., 2006. NR4A1, 2, 3 - an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol. Histopathol. 21, 533-540.
22. Lin, B.Z., Kolluri, S.K., Lin, F., Liu, W., Han, Y.H., Cao, X.H., Dawson, M.I., Reed, J.C., Zhang, X.K., 2004. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116, 527-540. (Pubitemid 38264430)
23. Liu, J.J., Zeng, H.N., Zhang, L.R., Zhan, Y.Y., Chen, Y., Wang, Y., Wang, J., Xiang, S.H., Liu, W.J., Wang, W.J., Chen, H.Z., Shen, Y.M., Su, W.J., Huang, P.Q., Zhang, H.K., Wu, Q., 2010. A unique pharmacophore for activation of the nuclear orphan receptor Nur77 in vivo and in vitro. Cancer Res. 70, 3628-3637.
24. Liu, Y., Xie, P.C., Zhang, D.R., Zhang, Q., 2012a. A mini review of nanosuspensions development. J. Drug Target. 20, 209-223.
25. Liu, Y., Zhang, D.R., Duan, C.X., Jia, L.J., Xie, P.C., Zheng, D.D., Wang, F.H., Liu, G.P., Hao, L.L., Zhang, X.S., Zhang, Q., 2012b. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J. Microencapsul. 29, 194-203.
26. Maruyama, K., Tsukada, T., Ohkura, N., Bandoh, S., Hosono, T., Yamaguchi, K., 1998. The NGFI-B subfamily of the nuclear receptor superfamily. Int. J. Oncol. 12, 1237-1243 (Review).
27. Moll, U.M., Marchenko, N., Zhang, X.-K., 2006. P53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25, 4725-4743. (Pubitemid 44187622)
28. Mosharraf, M., Nystrom, C., 1995. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int. J. Pharm. 122, 35-47.
29. Mou, D.S., Chen, H.B., Wan, J.L., Xu, H.B., Yang, X.L., 2011. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int. J. Pharm. 413, 237-244.
30. Muller, R.H., Keck, C.M., 2004. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113, 151-170. (Pubitemid 39237077)
31. Pei, L.M., Waki, H., Vaitheesvaran, B., Wilpitz, D.C., Kurland, I.J., Tontonoz, P., 2006. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. Nat. Med. 12, 1048-1055. (Pubitemid 44353386)
32. Sibayama-Imazu, T., Fujisawa, Y., Masuda, Y., Aiuchi, T., Nakajo, S., Itabe, H., Nakaya, K., 2008. Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei. J. Cancer Res. Clin. Oncol. 134, 803-812.
33. Thassu, D., Deleers, M., Pathak, Y., 2007. Nanoparticulate Drug Delivery Systems. Informa Healthcare, New York.
34. Thompson, J., Winoto, A., 2008. During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. J. Exp. Med. 205, 1029-1036. (Pubitemid 351679679)
35. Tsai, M.L., Tseng, L.Z., Chen, R.H., 2009. Two-stage microfluidization combined with ultrafiltration treatment for chitosan mass production and molecular weight manipulation. Carbohydr. Polym. 77, 767-772.
36. Verma, S., Lan, Y., Gokhale, R., Burgess, D.J., 2009a. Quality by design approach to understand the process of nanosuspension preparation. Int. J. Pharm. 377, 185-198.
37. Verma, S., Gokhale, R., Burgess, D.J., 2009b. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int. J. Pharm. 380, 216-222.
38. Wang, Y.C., Zhang, D.R., Liu, Z.P., Liu, G.P., Duan, C.X., Jia, L.J., Feng, F.F., Zhang, X.Y., Shi, Y.Q., Zhang, Q., 2010. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 21, 155104.
39. Winoto, A., Littman, D.R., 2002. Nuclear hormone receptors in T lymphocytes. Cell 109 (Suppl.), S57-S66. (Pubitemid 34457852)
40. Wu, Q., Liu, S., Ye, X.F., Huang, Z.W., Su, W.J., 2002. Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cell. Carcinogenesis 23, 1583-1592. (Pubitemid 35214942)
41. Yoon, K., Lee, S.O., Cho, S.D., Kim, K., Khan, S., Safe, S., 2011. Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. Carcinogenesis 32, 836-842.
42. Zhan, Y.Y., Du, X.P., Chen, H.Z., Liu, J.J., Zhao, B.X., Huang, D.H., Li, G.D., Xu, Q.Y., Zhang, M.Q., Weimer, B.C., Chen, D., Cheng, Z., Zhang, L.R., Li, Q.X., Li, S.W., Zheng, Z.H., Song, S.Y., Huang, Y.J., Ye, Z.Y., Su, W.J., Lin, S.C., Shen, Y.M., Wu, Q., 2008. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat. Chem. Biol. 4, 548-556.
43. Zhang, T.C., Chen, J.N., Zhang, Y., Shen, Q., Pan, W.S., 2011. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur. J. Pharm. Sci. 43, 174-179.